Latest Breaking News On - இறுதி ஒப்புதல் - Page 12 : comparemela.com

DBV Technologies Announces Change in U.S. Reporting Status and Final Approval of Global Restructuring Process Montrouge, France, January 7, 2021 DBV Technologies Announces Change in U.S. Reporting Status and Final Approval of Global Restructuring Process DBV Technologies S.A. (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that it has determined that it now qualifies as a U.S. domestic issuer rather than a foreign private issuer in the United States. As of January 1, 2021, DBV Technologies is subject to U.S. Securities and Exchange Commission (SEC) and other rules and regulations applicable to U.S. domestic issuers, in addition to applicable French and EU regulations. DBV will be required to file with the SEC periodic reports (including current reports on Form 8-K and quarterly reports on Form 10-Q) and registration statements on U.S. domestic issuer forms. Pursuant to SEC rules, the Company will pr

New yorkUnited statesFrance generalDaniel tasseAnne pollakAngela marcucciCompany annual report on formExchange commissionInternational financial reporting standardsCompany adssEuropean unionCompany universal registration documentAnnounces changeFinal approvalGlobal restructuringNasdaq stock market